University of Oklahoma
Patients with cancer have a higher incidence of AF but despite the higher incidence of AF in the cancer population, there are no randomized controlled trials (RCTs) for AF screening in this population. RCTs of AF screening in the general population have shown that screening can effectively detect AF earlier, and helps to identify candidates for appropriate anticoagulation that may lead to improvement in clinical outcomes.
Cancer
30-second ECG using the Kardia Mobile
routine care
NA
The Investigators will conduct an open label, prospective, pilot RCT. After informed consent, patients will be randomized 1:1 into screening or usual care. Screening will be done at a single time point. Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). Patients randomized to usual care will not receive a screening ECG. Primary outcome will be detection of newly diagnosed AF by screening vs usual care.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 480 participants |
| Masking : | NONE |
| Primary Purpose : | DIAGNOSTIC |
| Official Title : | Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial |
| Actual Study Start Date : | 2023-11-06 |
| Estimated Primary Completion Date : | 2024-12-31 |
| Estimated Study Completion Date : | 2025-07-30 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 65 Years to 90 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104